Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines

Br J Haematol. 2010 Jun;149(5):693-705. doi: 10.1111/j.1365-2141.2010.08160.x. Epub 2010 Apr 16.

Abstract

A joint working group established by the Haemato-oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Transplantation Society (BTS) has reviewed the available literature and made recommendations for the diagnosis and management of post-transplant lymphoproliferative disorder in adult recipients of solid organ transplants. This review details the therapeutic options recommended including reduction in immunosuppression (RIS), transplant organ resection, radiotherapy and chemotherapy. Effective therapy should be instituted before progressive disease results in declining performance status and multi-organ dysfunction. The goal of treatment should be a durable complete remission with retention of transplanted organ function with minimal toxicity.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Adult
  • Algorithms
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / therapeutic use
  • Combined Modality Therapy
  • Drug Administration Schedule
  • Evidence-Based Medicine / methods
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects
  • Immunotherapy, Adoptive / methods
  • Lymphoproliferative Disorders / etiology
  • Lymphoproliferative Disorders / therapy*
  • Organ Transplantation / adverse effects*
  • Prognosis
  • Reoperation
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Immunosuppressive Agents
  • Rituximab